Rigante D, Mazzoni MB, Esposito S. The cryptic interplay between systemic lupus erythematosus and infections. Autoimmun Rev. 2014;13(2):96–102.

CAS  PubMed  Google Scholar 

Hou C, Jin O, Zhang X. Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus. Clin Rheumatol. 2018;37(10):2699–705.

PubMed  Google Scholar 

Wu XY, Yang M, Xie YS, Xiao WG, Lin J, Zhou B, et al. Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort. Clin Rheumatol. 2019;38(1):107–15.

PubMed  Google Scholar 

Thong KM, Chan TM. Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis. Lupus. 2019;28(3):334–46.

CAS  PubMed  Google Scholar 

Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection. Expert Rev Clin Immunol. 2020;16(5):527–38.

CAS  PubMed  Google Scholar 

Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet (London, England). 2019;393(10188):2344–58.

PubMed  Google Scholar 

Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.

CAS  PubMed  Google Scholar 

Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156–62.

CAS  PubMed  Google Scholar 

Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D’Cruz DP, Abbs IC, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol. 2005;32(6):1047–52.

CAS  PubMed  Google Scholar 

Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol. 2003;30(7):1508–12.

CAS  PubMed  Google Scholar 

Li L, Wang H, Lin S, et al. Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi. 2002;41(7):476–9.

PubMed  Google Scholar 

Takeuchi T, Hashimoto H, Matsumoto M. Long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan. Mod Rheumatol. 2022;32(4):746–54.

PubMed  Google Scholar 

Jiang YP, Zhao XX, Chen RR, Xu ZH, Wen CP, Yu J. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis. Medicine. 2020;99(38): e22328.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang H, Zhou M, Han X, Yang Y, Yu X. Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis: a PRISMA-compliant meta-analysis. Medicine. 2020;99(33): e21121.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Tao MJ, Jin LR, Sheng J, Li Z, Peng H, et al. Effectiveness and safety of common therapeutic drugs for refractory lupus nephritis: a network meta-analysis. Exp Ther Med. 2020;19(1):665–71.

CAS  PubMed  Google Scholar 

Liu LL, Jiang Y, Wang LN, Yao L, Li ZL. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs. 2012;72(11):1521–33.

CAS  PubMed  Google Scholar 

Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine. 2010;89(4):227–35.

CAS  PubMed  Google Scholar 

Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69–78.

CAS  PubMed  Google Scholar 

Ko T, Koelmeyer R, Li N, Yap K, Yeo AL, Kent J, et al. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. Semin Arthritis Rheum. 2022;57: 152099.

PubMed  Google Scholar 

China National Health and Family Planning Commission. Act on ethical review system of biomedical research involving human subjects. Available at: http://www.gov.cn/gongbao/content/2017/content_5227817.htm.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

CAS  PubMed  Google Scholar 

Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17(2):75–92.

CAS  PubMed  Google Scholar 

González-Echavarri C, Capdevila O, Espinosa G, Suárez S, Marín-Ballvé A, González-León R, et al. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus. 2018;27(14):2253–61.

PubMed  Google Scholar 

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–12.

CAS  PubMed  PubMed Central  Google Scholar 

Subedi A, Magder LS, Petri M. Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. Rheumatol Int. 2015;35(10):1687–92.

CAS  PubMed  PubMed Central  Google Scholar 

Martínez-Martínez MU, Baranda-Cándido L, Abud-Mendoza C. Cutaneous papillomavirus infection in patients with rheumatoid arthritis or systemic lupus erythematosus. A case–control study. Lupus. 2013;22(9):948–52.

PubMed  Google Scholar 

Zamora LD, Collante MTM, Navarra SV. Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus. Int J Rheum Dis. 2020;23(2):197–202.

CAS  PubMed  Google Scholar 

Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014;34(12):1765–71.

CAS  PubMed  Google Scholar 

Hsu HC, Chang YS, Hou TY, Chen LF, Hu LF, Lin TM, et al. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study. Clin Rheumatol. 2021;40(9):3755–63.

PubMed  PubMed Central  Google Scholar 

Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients? A mini-review. Brazil J Infect Dis: Off Publ Brazil Soc Infect Dis. 2006;10(2):132–8.

Google Scholar 

Kaplan B, Meier-Kriesche HU, Jacobs MG, Friedman G, Bonomini L, DeFranco P, et al. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis. 1999;34(1):65–8.

CAS  PubMed  Google Scholar 

Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother. 1998;42(2):216–22.

CAS  PubMed  PubMed Central  Google Scholar 

Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, Calvo-Alén J, Del Campo V, Olivé-Marqués A, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47(1):38–45.

PubMed  Google Scholar 

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–45.

CAS  PubMed  Google Scholar 

Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, et al. Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications. Arthritis Rheumatol (Hoboken, NJ). 2017;69(2):387–97.

CAS  Google Scholar 

Singh JA, Hossain A, Kotb A, Wells G. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137.

PubMed  PubMed Central  Google Scholar 

Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2015;24(14):1520–8.

CAS  PubMed  Google Scholar 

Song GG, Lee YH. Comparison of treatment response and serious infection using tacrolimus, tacrolimus with mycophenolate mofetil, in comparison to cyclophosphamide as induction treatment for lupus nephritis. Int J Clin Pharmacol Ther. 2020;58(10):550–6.

CAS  PubMed  Google Scholar 

Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1):e1–45.

PubMed  Google Scholar 

Mok CC, Yap DY, Navarra SV, Liu ZH, Zhao MH, Lu L, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton). 2014;19(1):11–20.

PubMed  Google Scholar 

Weng MY, Weng CT, Liu MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol. 2010;29(7):771–5.

PubMed  Google Scholar 

Koo HS, Kim YC, Lee SW, Kim DK, Oh KH, Joo KW, et al. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus. 2011;20(13):1442–9.

CAS  PubMed  Google Scholar 

He J, Li Z. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatology (Oxford). 2023;62(Suppl 1):i22–9.

CAS  PubMed  Google Scholar 

Dave V, Polkinghorne KR, Leong KG, Kanellis J, Mulley WR. Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. Sci Rep. 2020;10(1):19379.

CAS  PubMed  PubMed Central